Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12626001371381p
Ethics application status
Submitted, not yet approved
Date submitted
26/10/2026
Date registered
16/11/2026
Date last updated
16/11/2026
Date data sharing statement initially provided
16/11/2026
Type of registration
Prospectively registered
Titles & IDs
Public title
Safety and ease of use of a heat-activated gel mixed with donor bone to rebuild jawbone during dental implant surgery, without a barrier membrane
Query!
Scientific title
A Study to Investigate the Safety and Procedural Feasibility of Tegenix Combined with Allograft Corticocancellous Bone Particles for Guided Bone Regeneration During Dental Implant Placement
Query!
Additional trial identifiers [1]
318734
0
TP-GBR-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PET C
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Peri-implant bony dehiscence defect
343962
0
Query!
Alveolar bone deficiency
343963
0
Query!
Partial edentulism
343964
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
340102
340102
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Single-arm. At implant placement (Day 0), once a facial peri-implant bony dehiscence defect is confirmed intraoperatively, the investigator performs guided bone regeneration (GBR) by mixing Tegenix with allograft bone and applying the composite directly to fill the defect, without a cell-occlusive barrier membrane. Tegenix is a sterile, single-use, ready-to-use 1 mL syringe of a synthetic thermoresponsive polymer, PNPHO (poly(N-isopropylacrylamide-co-N-acryloxysuccinimide-co-(2-hydroxyethyl methacrylate-polylactide)-co-oligo(ethylene glycol) monomethyl ether methacrylate)), at 280 mg/mL in phosphate buffered saline. Each 1 mL device is mixed with 2 cc (1 g) of a human allograft corticocancellous bone particle preparation included on the Australian Register of Therapeutic Goods (ARTG) (Oravance corticocancellous bone, ARTG 277310, Australian Biotechnologies Pty Ltd), a 1:1 ratio by weight (1:2 by volume). A maximum of 4 devices (4 mL, about 8 cc of composite) may be used per participant. The polymer gels at body temperature to hold the graft in place and resorbs within about 30 days. Mixing and application of the composite takes approximately 5 minutes, within an implant placement and GBR procedure of approximately 5 -15 minutes. If the composite cannot be positioned as intended, the surgeon may remove it and complete the augmentation conventionally (intraoperative conversion); the participant stays in the study for safety follow-up. The procedure is performed once, by a specialist periodontist. Adherence is ensured by direct intraoperative application and recorded in the electronic case report form (eCRF) with device lot and number of devices used. A research cone beam computed tomography (CBCT) scan no later than Day 7 confirms the composite has stayed in place. Stage II surgery at Month 6 is routine care under local anaesthetic: a flap is raised to expose the implant and grafted site, the cover screw is replaced with a healing abutment, and the flap is stitched closed. While the site is open, the remaining defect is measured, bone quality is graded, implant stability is measured and a trephine core of the regenerated bone is taken for histology. Follow-up continues to Month 20 after GBR.
Query!
Intervention code [1]
335630
0
Treatment: Surgery
Query!
Description of the comparator or control
No control group. All participants receive the Tegenix and allograft composite.
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
347249
0
Incidence and nature of adverse events, including adverse device effects and serious adverse events
Query!
Assessment method [1]
347249
0
Clinical examination, participant report and medical record review, coded by MedDRA
Query!
Timepoint [1]
347249
0
From the start of the Day 0 guided bone regeneration (GBR) procedure to the end of study visit, assessed at Day 7, Day 14, Month 1, Month 3, Month 6, Month 12 and Month 20 post-GBR (primary timepoint: Month 20 post-GBR)
Query!
Primary outcome [2]
347250
0
Incidence of device deficiencies
Query!
Assessment method [2]
347250
0
Investigator report on the device deficiency form
Query!
Timepoint [2]
347250
0
Day 0 (application) to Month 20 post-GBR
Query!
Primary outcome [3]
347251
0
Procedural feasibility (composite): time to perform GBR, retention of the composite at the intended site after soft tissue exposure, surgical time and surgical complexity compared with conventional membrane GBR (each scored 1 to 3)
Query!
Assessment method [3]
347251
0
Clinician Questionnaire completed by the surgeon
Query!
Timepoint [3]
347251
0
Day 0 (immediately after surgery)
Query!
Secondary outcome [1]
469692
0
Change in bone dimensions at the augmented site
Query!
Assessment method [1]
469692
0
Cone beam computed tomography (CBCT), measured by a Specialist Oral and Maxillofacial Radiologist at Envision Medical Imaging, independent of the surgical team
Query!
Timepoint [1]
469692
0
Pre-operatively (screening CBCT, before Day 0) and Month 6 post-GBR (Stage II surgery)
Query!
Secondary outcome [2]
469693
0
Clinical bone quality at the augmented site
Query!
Assessment method [2]
469693
0
Tissue Quality (TQ) score, graded by the operating surgeon on tactile assessment during Stage II surgery
Query!
Timepoint [2]
469693
0
Month 6 post-GBR (Stage II surgery)
Query!
Secondary outcome [3]
469694
0
Histological characteristics of newly formed bone: new bone formation, residual graft particles, connective tissue, inflammatory infiltrate and, where the core allows, histomorphometry
Query!
Assessment method [3]
469694
0
Histological analysis of a trephine core biopsy by an oral pathologist or oral histologist at an independent laboratory, blinded to participant identity
Query!
Timepoint [3]
469694
0
Month 6 post-GBR (Stage II surgery)
Query!
Secondary outcome [4]
469695
0
Soft tissue swelling and oedema at the augmented site
Query!
Assessment method [4]
469695
0
Graded none, mild, moderate or severe (5-point scale of Becker et al. 2009) by the treating clinician or a board-registered dental hygienist at clinical examination; recorded in the eCRF
Query!
Timepoint [4]
469695
0
Day 7, Day 14, Month 1, Month 3 and Month 6 post-GBR
Query!
Secondary outcome [5]
469696
0
Soft tissue dehiscence at the augmented site
Query!
Assessment method [5]
469696
0
Recorded as present or absent and, where present, the tissue condition graded as uneventful, inflamed, swollen, fibrin, plaque or necrotic (Becker et al. 2009), by the treating clinician or a board-registered dental hygienist at clinical examination; recorded in the eCRF
Query!
Timepoint [5]
469696
0
Day 7, Day 14, Month 1, Month 3 and Month 6 post-GBR
Query!
Secondary outcome [6]
469697
0
Change from pre-operative baseline in post-operative pain
Query!
Assessment method [6]
469697
0
100 mm visual analogue scale (VAS, 0 to 100) completed by the participant: baseline at the site before surgery, then in the Participant Diary within 24 hours of each timepoint
Query!
Timepoint [6]
469697
0
Day 0 (pre-operative baseline), and Day 1, Day 7, Day 14, Month 1 and Month 3 post-GBR
Query!
Secondary outcome [7]
469698
0
Analgesic consumption
Query!
Assessment method [7]
469698
0
Time in seconds from first incision to completion of primary closure, recorded by the operating surgeon in the eCRF
Query!
Timepoint [7]
469698
0
Day 0, recorded at completion of the GBR procedure
Query!
Secondary outcome [8]
469699
0
Surgical time
Query!
Assessment method [8]
469699
0
Time in seconds from first incision to completion of primary closure, recorded by the operating surgeon in the eCRF
Query!
Timepoint [8]
469699
0
Day 0, recorded at completion of the GBR procedure
Query!
Secondary outcome [9]
469700
0
Implant Survival
Query!
Assessment method [9]
469700
0
Clinical examination by the investigator for presence of the implant in function without mobility, and review of the clinical record for any implant removal, re-operation or re-implantation; recorded in the eCRF
Query!
Timepoint [9]
469700
0
Month 6 (Stage II surgery), Month 12 and Month 20 post-GBR
Query!
Secondary outcome [10]
469701
0
Peri-implant health
Query!
Assessment method [10]
469701
0
Clinical examination with a graduated periodontal probe: probing depth to the nearest mm, and bleeding and exudation on probing (present or absent), at 6 sites per implant restoration; recorded in the eCRF
Query!
Timepoint [10]
469701
0
Month 12 and Month 20 post-GBR (after prosthetic restoration)
Query!
Secondary outcome [11]
469703
0
Need for secondary bone augmentation
Query!
Assessment method [11]
469703
0
Investigator records in the eCRF whether any additional autologous, xenograft or allograft augmentation was performed at Stage II surgery (yes or no)
Query!
Timepoint [11]
469703
0
Month 6 post-GBR (Stage II surgery)
Query!
Secondary outcome [12]
469704
0
Participant satisfaction and patient-reported outcomes
Query!
Assessment method [12]
469704
0
Patient-Reported Outcomes in Dental Implant Therapy, 17-item instrument (PRO-DIT-17), and study-specific Participant Diary items (implant complications since restoration, oral health and smoking history, cost of treatment), completed by the participant will be assessed together as a composite secondary outcome.
Query!
Timepoint [12]
469704
0
Month 20 post-GBR
Query!
Eligibility
Key inclusion criteria
Adults aged 18 to 80 years; partially edentulous with at least 1 missing tooth in the maxilla or mandible needing a fixed implant-supported restoration; tooth at the implant site extracted at least 6 weeks earlier with no other surgery at the site (such as ridge preservation); vertical bone height of 8 mm or more and favourable primary implant stability; a facial peri-implant bony dehiscence defect after implant placement requiring simultaneous guided bone regeneration (confirmed intraoperatively); planned Stage II surgery at about 6 months; full mouth plaque score and bleeding on probing of 25% or less; probing depths of 4 mm or less (or deeper without bleeding); willing and able to give written informed consent and attend all visits to Month 20.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
Any condition contraindicating implant surgery or completion of the study, including documented renal disease, planned chemotherapy or radiotherapy, cardiovascular, immune, autoimmune, musculoskeletal, nervous system or metabolic disorders (including uncontrolled diabetes), neoplasm, active infection, or disorders of bone metabolism including antiresorptive or antiangiogenic therapy; smoking more than 10 cigarettes a day or regular vaping; pregnancy, lactation, or women of childbearing potential not using acceptable contraception; psychological condition affecting understanding of the study; another clinical study or investigational product within 4 weeks; current or planned immunosuppressive therapy, including systemic corticosteroids at immunosuppressive doses; mucosal disease or oral lesions likely to impair healing; active infection at or next to the site; previous radiotherapy to the jaws; previous regenerative treatment or materials likely to hinder bone regeneration at the site; known hypersensitivity to any component of Tegenix or the allograft.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Descriptive statistics only; no hypothesis testing. Sample size of 10 is not based on a power calculation and is intended to give descriptive estimates of safety, defect resolution, bone quality and histology, and their variability, to power a later controlled study. No imputation of missing data. A statistical analysis plan will be approved before database lock.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
30/01/2027
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
30/07/2027
Query!
Actual
Query!
Date of last data collection
Anticipated
30/12/2028
Query!
Actual
Query!
Sample size
Target
10
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
WA
Query!
Recruitment hospital [1]
30396
0
West Perth Periodontics - West Perth
Query!
Recruitment postcode(s) [1]
46815
0
6005 - West Perth
Query!
Funding & Sponsors
Funding source category [1]
323305
0
Commercial sector/Industry
Query!
Name [1]
323305
0
Tetratherix Technology Pty Limited
Query!
Address [1]
323305
0
Query!
Country [1]
323305
0
Australia
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Tetratherix Technology Pty Limited
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
326274
0
None
Query!
Name [1]
326274
0
Query!
Address [1]
326274
0
Query!
Country [1]
326274
0
Query!
Ethics approval
Ethics application status
Submitted, not yet approved
Query!
Ethics committee name [1]
321694
0
St Vincent’s Hospital Human Research Ethics Committee
Query!
Ethics committee address [1]
321694
0
https://svhs.org.au/home/research-education/research-office
Query!
Ethics committee country [1]
321694
0
Australia
Query!
Date submitted for ethics approval [1]
321694
0
02/11/2026
Query!
Approval date [1]
321694
0
Query!
Ethics approval number [1]
321694
0
Query!
Summary
Brief summary
When a dental implant is placed, part of the implant surface is often left without bone covering it. The usual repair packs bone graft particles into the gap and covers them with a membrane, which can be fixed with tacks or screws and is technically demanding. Tegenix is a new synthetic gel that is liquid at room temperature and sets at body temperature. Mixed with donor bone particles, it is designed to hold the graft in place without a membrane, and it dissolves within about 30 days. This is the first study of Tegenix in people. It will check whether Tegenix mixed with donor bone is safe and practical to use when repairing these bone gaps during implant surgery. Ten adults having implant surgery at one specialist periodontal practice in Perth will receive the treatment (up to 15 if participants need to be replaced). The first 3 are treated one at a time, with an independent safety review before more people join. Participants are followed for about 20 months. At about 6 months, when the implant is uncovered, the new bone is measured, scanned and sampled. There is no comparison group; results will be described rather than statistically tested.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
154550
0
Prof DAX CALDER
Query!
Address
154550
0
West Perth Periodontics, 21 Rheola Street, West Perth WA 6005
Query!
Country
154550
0
Australia
Query!
Phone
154550
0
+61 89321 7581
Query!
Fax
154550
0
Query!
Email
154550
0
[email protected]
Query!
Contact person for public queries
Name
154551
0
Clinical Professor Dax Calder,
Query!
Address
154551
0
West Perth Periodontics, 21 Rheola Street, West Perth WA 6005
Query!
Country
154551
0
Australia
Query!
Phone
154551
0
+61893217581
Query!
Fax
154551
0
Query!
Email
154551
0
[email protected]
Query!
Contact person for scientific queries
Name
154552
0
Dr Ali Fathi of Tetratherix Technology Pty Limited
Query!
Address
154552
0
Tetratherix Technology - Unit 29, 34–36 Ralph Street, Alexandria NSW 2015. Country: Australia
Query!
Country
154552
0
Australia
Query!
Phone
154552
0
+61395625333
Query!
Fax
154552
0
Query!
Email
154552
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment:
small single-site first-in-human device study under commercial sponsorship; data include identifiable clinical images and CBCT scans; summary results will be reported.
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF